http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
Merrimack and Baxalta Announce Initiation of Phase 1 Study of MM-151 in Combination with the ONIVYDE® (irinotecan liposome injection) Regimen in Metastatic Colorectal Cancer
-
Gadeta Closes EUR 7 Million Series A Financing to Advance Novel Cancer Immunotherapies to the Clinic
-
Merrimack Pharma (MACK) Issues Positive OS Update from Phase 3 NAPOLI-1 Study (BXLT)
-
Updated Data Shows ONIVYDE® (irinotecan liposome injection) Combination Regimen Increased One Year Survival by 63% in Patients with Metastatic Pancreatic Cancer
-
Merrimack and Baxalta Announce Publication of the ONIVYDE™ (irinotecan liposome injection) NAPOLI-1 Study in The Lancet
-
Merrimack and Baxalta Announce Enrollment of First Patient in Phase 2 Study of ONIVYDE™ (irinotecan liposome injection) in Previously Untreated Front-line Metastatic Pancreatic Cancer
-
Merrimack Announces U.S. FDA Approval of ONIVYDE™ (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer
-
Xenetic Biosciences, Inc.'s Major Strategic Shareholders Enter Into Long Term Lock-Up Agreements
-
Top 10 News for 8/3 - 8/7: July Payroll Gains Fall Short; Twitter Bloodshed Continues; Cable Cutting Concern Hits Media Names
-
Pre-Open Stock Movers 07/29: (CYT) (RUBI) (BWLD) Higher; (YELP) (DATA) (TWTR) Lower (more...)
-
After-Hours Stock Movers 07/28: (RUBI) (BWLD) (CTXS) Higher; (YELP) (AKAM) (TWTR) Lower (more...)

